glp-1 small molecule In the ACHIEVE-1 phase 3 trial, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes A novel approach to exploit
Pay in 4 interest-free payments of $6.43 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
























